Telos Capital Management Inc. Buys 2,730 Shares of ResMed Inc. $RMD

Posted by Brian Himes on Jun 23rd, 2026

Telos Capital Management Inc. grew its stake in ResMed Inc. (NYSE:RMD – Free Report) by 8.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,799 shares of the medical equipment provider’s stock after acquiring an additional 2,730 shares during the quarter. Telos Capital Management Inc.’s holdings in ResMed were worth $8,036,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. First Trust Advisors LP grew its stake in ResMed by 240.9% in the fourth quarter. First Trust Advisors LP now owns 1,517,592 shares of the medical equipment provider’s stock valued at $365,542,000 after purchasing an additional 1,072,394 shares during the last quarter. Norges Bank purchased a new stake in shares of ResMed during the fourth quarter valued at about $249,068,000. Deutsche Bank AG boosted its holdings in shares of ResMed by 126.0% in the 4th quarter. Deutsche Bank AG now owns 1,413,477 shares of the medical equipment provider’s stock valued at $340,464,000 after buying an additional 787,949 shares in the last quarter. Morgan Stanley boosted its holdings in shares of ResMed by 25.0% in the 4th quarter. Morgan Stanley now owns 2,891,697 shares of the medical equipment provider’s stock valued at $696,523,000 after buying an additional 578,559 shares in the last quarter. Finally, Swedbank AB grew its position in shares of ResMed by 103.1% in the 4th quarter. Swedbank AB now owns 1,102,476 shares of the medical equipment provider’s stock worth $265,553,000 after buying an additional 559,765 shares during the last quarter. 54.98% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total transaction of $450,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $193.96, for a total value of $968,054.36. Following the sale, the chief executive officer owned 466,256 shares in the company, valued at approximately $90,435,013.76. The trade was a 1.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 16,973 shares of company stock valued at $3,580,754 in the last 90 days. 0.65% of the stock is currently owned by company insiders.

ResMed Stock Down 0.1%

RMD stock opened at $188.52 on Tuesday. The stock has a market capitalization of $27.35 billion, a PE ratio of 18.18, a price-to-earnings-growth ratio of 1.20 and a beta of 0.80. ResMed Inc. has a 52 week low of $180.26 and a 52 week high of $293.81. The company has a quick ratio of 2.33, a current ratio of 3.01 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $205.95 and a 200 day moving average of $232.61.

ResMed (NYSE:RMD – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.07. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The business had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same quarter in the prior year, the business posted $2.37 EPS. ResMed’s revenue for the quarter was up 10.8% compared to the same quarter last year. Sell-side analysts forecast that ResMed Inc. will post 11.13 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Thursday, May 14th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend was Thursday, May 14th. ResMed’s dividend payout ratio is presently 23.14%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on RMD shares. Wall Street Zen cut shares of ResMed from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Evercore set a $255.00 price target on shares of ResMed and gave the stock an “outperform” rating in a report on Monday, April 13th. KeyCorp reduced their price target on ResMed from $290.00 to $266.00 and set an “overweight” rating on the stock in a research report on Monday. Wells Fargo & Company lowered their price objective on ResMed from $270.00 to $227.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Finally, Robert W. Baird set a $225.00 target price on ResMed in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, ResMed has an average rating of “Moderate Buy” and a consensus price target of $270.82.

Read Our Latest Stock Report on ResMed

ResMed Company Profile

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.